Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.69 |
| ▸ | PDE2A | O00408 | 16/20 | 0.69 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.55 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115262 | 0.87 | PDE10A (0.72) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4129550 | 0.83 | PDE10A (0.80) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4121094 | 0.82 | PDE10A (0.78) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4126852 | 0.82 | PDE10A (1.00) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4132733 | 0.81 | PDE10A (0.78) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4119110 | 0.80 | PDE10A (0.78) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4132632 | 0.80 | PDE10A (0.66) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL4107756 | 0.79 | PDE10A (0.71) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL3996062 | 0.79 | PDE10A (0.58) | PDE10APDE2APDE7APDE5APDE11A | |
| SCHEMBL3321743 | 0.78 | PDE2A (0.71) | PDE10APDE2APDE7APDE5APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009070583-A1 | PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | claimed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | claimed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | PDE12, PDE5A, PDE3A | PDE10A 10/4885PDE2A 4/4885PDE7A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.